BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 15195930)

  • 1. Antibody therapy for non-Hodgkin's lymphoma.
    Ansell SM
    Curr Opin Mol Ther; 2004 Apr; 6(2):175-81. PubMed ID: 15195930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD20-targeted therapy: a breakthrough in the treatment of non-Hodgkin's lymphoma.
    van Meerten T; Hagenbeek A
    Neth J Med; 2009; 67(7):251-9. PubMed ID: 19687518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab: review and clinical applications focusing on non-Hodgkin's lymphoma.
    King KM; Younes A
    Expert Rev Anticancer Ther; 2001 Aug; 1(2):177-86. PubMed ID: 12113023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of the anti-CD20 antibody rituximab in hematopoietic stem cell transplantation for non-Hodgkin's lymphoma.
    Naparstek E
    Curr Hematol Rep; 2005 Jul; 4(4):276-83. PubMed ID: 16009042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Rituximab].
    Okamoto R; Maeda Y; Sasaki T
    Gan To Kagaku Ryoho; 2003 Aug; 30(8):1085-93. PubMed ID: 12938262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel and engineered anti-B-cell monoclonal antibodies for non-Hodgkin's lymphoma.
    Martin P; Furman RR; Ruan J; Elstrom R; Barrientos J; Niesvizky R; Coleman M; Leonard JP
    Semin Hematol; 2008 Apr; 45(2):126-32. PubMed ID: 18381108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
    Marcus R; Hagenbeek A
    Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody and immunomodulatory agents in the treatment of indolent non-Hodgkin's lymphoma.
    LaCasce AS; Freedman AS
    Semin Hematol; 2008 Apr; 45(2):85-9. PubMed ID: 18381102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab immunotherapy for non-Hodgkin's lymphoma.
    White CA
    Cancer Biother Radiopharm; 1999 Aug; 14(4):241-50. PubMed ID: 10850310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma.
    Leonard JP; Coleman M; Ketas J; Ashe M; Fiore JM; Furman RR; Niesvizky R; Shore T; Chadburn A; Horne H; Kovacs J; Ding CL; Wegener WA; Horak ID; Goldenberg DM
    J Clin Oncol; 2005 Aug; 23(22):5044-51. PubMed ID: 15955901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Rituximab in the treatment of indolent non-Hodgkin's lymphoma].
    Aurer I; Mitrović Z; Radman I; Kovacević-Metelko J; Nemet D; Serventi-Seiwerth R; Stern-Padovan R; Jakic-Razumović J; Nola M; Zupancić-Salek S; Sertić D; Labar B
    Lijec Vjesn; 2004; 126(11-12):307-11. PubMed ID: 16082888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevation of activated platelet-dependent chemokines in patients with anti-CD20 monoclonal antibody (rituximab)-treated non-Hodgkin's lymphoma.
    Nomura S; Ishii K; Kamitsuji Y; Uoshima N; Ishikawa E; Kitayama H; Hayashi K
    Clin Appl Thromb Hemost; 2007 Apr; 13(2):206-12. PubMed ID: 17456632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Non-cytostatic treatment of malignancies. Anti-CD20 monoclonal antibody (Rituximab, Mabthera) in the treatment of non-Hodgkin's lymphoma].
    Mayer J; Navrátil M; Vásová J; Vorlícek J
    Vnitr Lek; 2001 Sep; 47 Suppl 1():57-62. PubMed ID: 11693064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
    Jazirehi AR; Bonavida B
    Oncogene; 2005 Mar; 24(13):2121-43. PubMed ID: 15789036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intrapleural instillation of rituximab for the treatment of malignant pleural effusions in NHL.
    Schmidt HH; Renner H; Linkesch W
    Haematologica; 2004 Nov; 89(11):ECR39. PubMed ID: 15533844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab in B-cell disorders other than non-Hodgkin's lymphoma.
    Bosly A; Keating MJ; Stasi R; Bradstock K
    Anticancer Drugs; 2002 Nov; 13 Suppl 2():S25-33. PubMed ID: 12710588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Monoclonal antibody therapy for malignant lymphoma].
    Buske C; Dreyling M; Unterhalt M; Hiddemann W
    Med Klin (Munich); 2005 Jan; 100(1):14-24. PubMed ID: 15654538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyond.
    Zhou Y; Zhang L; Romaguera J; Delasalle K; Han X; Du X; Kwak L; Yi Q; Wang M
    Am J Hematol; 2008 Feb; 83(2):144-9. PubMed ID: 17722077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma.
    Collins-Burow B; Santos ES
    Expert Rev Anticancer Ther; 2007 Mar; 7(3):257-73. PubMed ID: 17338647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.